These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 10367752)

  • 1. Phase I and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs.
    Waddle JR; Fine RL; Case BC; Trogdon ML; Tyczkowska K; Frazier D; Page RL
    Cancer Chemother Pharmacol; 1999; 44(1):74-80. PubMed ID: 10367752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
    Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
    Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
    Darvari R; Boroujerdi M
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood.
    Pollack IF; DaRosso RC; Robertson PL; Jakacki RL; Mirro JR; Blatt J; Nicholson S; Packer RJ; Allen JC; Cisneros A; Jordan VC
    Clin Cancer Res; 1997 Jul; 3(7):1109-15. PubMed ID: 9815790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
    Rubin EH; de Alwis DP; Pouliquen I; Green L; Marder P; Lin Y; Musanti R; Grospe SL; Smith SL; Toppmeyer DL; Much J; Kane M; Chaudhary A; Jordan C; Burgess M; Slapak CA
    Clin Cancer Res; 2002 Dec; 8(12):3710-7. PubMed ID: 12473580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Shin SC; Choi JS
    Anticancer Drugs; 2009 Aug; 20(7):584-8. PubMed ID: 19491656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
    Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
    Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.
    Fine RL; Chen J; Balmaceda C; Bruce JN; Huang M; Desai M; Sisti MB; McKhann GM; Goodman RR; Bertino JS; Nafziger AN; Fetell MR
    Clin Cancer Res; 2006 Oct; 12(19):5770-6. PubMed ID: 17020983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
    Piao Y; Shin SC; Choi JS
    Biopharm Drug Dispos; 2008 May; 29(4):245-9. PubMed ID: 18338336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats.
    Vaidyanathan S; Boroujerdi M
    Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
    O'Day SJ; Boasberg PD; Kristedja TS; Martin M; Wang HJ; Fournier P; Cabot M; DeGregorio MW; Gammon G
    Cancer; 2001 Aug; 92(3):609-19. PubMed ID: 11505406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
    Li C; Kim M; Choi H; Choi J
    Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
    Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
    Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
    Thakkar SG; Peereboom D; Olencki T; Jacobs B; Elson P; Rybicki L; Lindner DJ; Borden EC
    J Interferon Cytokine Res; 2006 Nov; 26(11):800-3. PubMed ID: 17115898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.